ReviewNature reviews. Clinical oncology2021
PD-L1 as a biomarker of response to immune-checkpoint inhibitors.
Deborah Blythe Doroshow et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
957 papers cite itlatest 60 shown
this paperpooled ittrialcites it